



## News Release

### **Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting**

**OSAKA, Japan and CAMBRIDGE, Massachusetts, March 26, 2025** - Takeda (TSE:4502/NYSE:TAK) announced its Board of Directors decided today to propose the re-election of all current directors (excluding Audit and Supervisory Committee Members) at the 149th Ordinary General Meeting of Shareholders on June 25, 2025.

#### Candidates for Directors Who Are Not Audit and Supervisory Committee Members

Name	Category		Expected Role
Christophe Weber	Internal	Existing	Representative Director, President & Chief Executive Officer
Milano Furuta	Internal	Existing	Director, Chief Financial Officer
Andrew Plump	Internal	Existing	Director, President, Research & Development
Masami Iijima	External	Existing	External Director, Chair of the Board Meeting
Ian Clark	External	Existing	External Director
Steven Gillis	External	Existing	External Director
Emiko Higashi	External	Existing	External Director
John Maraganore	External	Existing	External Director
Michel Orsinger	External	Existing	External Director
Miki Tsusaka	External	Existing	External Director

The tenure for non-Audit and Supervisory Committee director is one year.

The following four Directors who are Audit and Supervisory Committee members were elected at the 148th Ordinary General Meeting of Shareholders held in 2024 and their terms of office will continue until the 150th Ordinary General Meeting of Shareholders held in 2026.

Name	Category	Role
Koji Hatsukawa	External	External Director, Head of Audit and Supervisory Committee
Jean-Luc Butel	External	External Director, Audit and Supervisory Committee Member
Yoshiaki Fujimori	External	External Director, Audit and Supervisory Committee Member
Kimberly A. Reed	External	External Director, Audit and Supervisory Committee Member

The tenure for Audit and Supervisory Committee director is two years.

As announced last January 30\*, Julie Kim, currently the president of the U.S. Business Unit and U.S. country head, will succeed Christophe Weber as Takeda's president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Takeda's Board of Directors will propose Mrs. Kim as a new candidate for election to the Board at the 150th Ordinary General Meeting of Shareholders to be held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda.

\* Please refer to "[Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026](#)"

Note:

1. The role of the directors who are not Audit and Supervisory Committee Members will be determined at the Board of Directors meeting to be held after the 149th Ordinary General Meeting of Shareholders.
2. The members of the Nomination Committee and Compensation Committee will be discussed and determined at the Board of Directors meeting to be held after the 149th Ordinary General Meeting of Shareholders.

### **About Takeda**

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](http://www.takeda.com).

Media Contacts:

Global Media

Brendan Jennings

[brendan.jennings@takeda.com](mailto:brendan.jennings@takeda.com)

+81 80-2705-8259

**Important Notice**

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

###